NRX PHARMACEUTICALS INC
NASDAQ: NRXP (NRX Pharmaceuticals, Inc.)
Last update: 2 days ago, 12:52AM2.20
0.04 (1.85%)
| Previous Close | 2.16 |
| Open | 2.13 |
| Volume | 353,472 |
| Avg. Volume (3M) | 1,050,950 |
| Market Cap | 72,748,784 |
| Price / Earnings (Forward) | 1.25 |
| Price / Sales | 37.65 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Diluted EPS (TTM) | -1.96 |
| Current Ratio (MRQ) | 0.220 |
| Operating Cash Flow (TTM) | -10.45 M |
| Levered Free Cash Flow (TTM) | 3.23 M |
| Return on Assets (TTM) | -191.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NRX Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.88% |
| % Held by Institutions | 13.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bleakley Financial Group, Llc | 31 Dec 2025 | 117,204 |
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2025 | 37,873 |
| Chicago Partners Investment Group Llc | 31 Dec 2025 | 33,421 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (HC Wainwright & Co., 1,945.46%) | Buy |
| Median | 34.00 (1,445.46%) | |
| Low | 25.00 (BTIG, 1,036.36%) | Buy |
| Average | 34.67 (1,475.91%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 34.00 (1,445.45%) | Buy | 1.73 |
| 17 Feb 2026 | 34.00 (1,445.45%) | Buy | 1.80 | |
| HC Wainwright & Co. | 03 Mar 2026 | 45.00 (1,945.45%) | Buy | 1.80 |
| BTIG | 18 Feb 2026 | 25.00 (1,036.36%) | Buy | 1.78 |
| 15 Jan 2026 | 25.00 (1,036.36%) | Buy | 2.15 |
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date |
| 14 Jan 2026 | Announcement | NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |